Director/PDMR Shareholding

RNS Number : 3674Q

Destiny Pharma PLC

05 June 2018

 

 Destiny Pharma plc

("Destiny Pharma" or "the Company")

Director/PDMR Shareholding

Brighton, United Kingdom - 5 June 2018 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), announces that Sir Nigel Rudd, Non-Executive Chairman of the Company, has today notified the Company that, on 4 June 2018, he and his wife have purchased a total of 74,900 ordinary shares of 1 pence each in the Company ("Ordinary Shares") at a price of 110.04 pence per share.

Following this notification, Sir Nigel Rudd, together with connected parties, has a beneficial holding of 1,229,900 Ordinary Shares (which represents 2.82 per cent. of the issued share capital of the Company).

The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sir Nigel Rudd
2	Reason for the notification
a)	Position/status	Non-Executive Chairman
b)	Initial notification  / Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code:	Ordinary shares of 1 pence each ISIN: GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares into ISA
c)	Price(s) and volume(s)	Price(s) Volume(s) 110.04 pence 39,100
d)	Aggregated information	N/A
e)	Date of the transaction	4 June 2018
f)	Place of the transaction	London Stock Exchange, AIM

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Lady Lesley Rudd
2	Reason for the notification
a)	Position/status	Person closely associated to Sir Nigel Rudd, Non-Executive Chairman
b)	Initial notification  / Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Destiny Pharma plc
b)	LEI	213800O9WH9Z38EHAC95
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code:	Ordinary shares of 1 pence each ISIN: GB00BDHSP575
b)	Nature of the transaction	Purchase of Ordinary Shares into ISA
c)	Price(s) and volume(s)	Price(s) Volume(s) 110.04 pence 35,800
d)	Aggregated information	N/A
e)	Date of the transaction	4 June 2018
f)	Place of the transaction	London Stock Exchange, AIM

For further information, please contact:

Destiny Pharma plc

Neil Clark, CEO

Simon Sacerdoti, CFO

[e-mail] 

[phone]

FTI Consulting

Simon Conway / Victoria Foster Mitchell

[e-mail] 

[phone]

Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker)

Philip Davies / Will Goode, Corporate Finance

Andrew Keith, Healthcare Equity Sales

[phone]

finnCap Ltd (Joint Broker)

Geoff Nash /Kate Bannatyne, Corporate Finance

Alice Lane, Corporate Broking

[phone]

About Destiny Pharma

Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the World Health Organisation (WHO) and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com 

 

END

 

 

DSHLLFSLREIEIIT